Visudyne(verteporfin)
Visudyne (verteporfin) is a small molecule pharmaceutical. Verteporfin was first approved as Visudyne on 2000-04-12. It is used to treat choroidal neovascularization in the USA. It has been approved in Europe to treat degenerative myopia and macular degeneration.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Visudyne
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Verteporfin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VISUDYNE | Bausch Health Companies | N-021119 RX | 2000-04-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| visudyne | New Drug Application | 2025-08-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| choroidal neovascularization | — | D020256 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3396 | Injection, verteporfin, 0.1 mg |
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 5 | 22 | 14 | 13 | 6 | 55 |
| Choroidal neovascularization | D020256 | — | — | 3 | 10 | 8 | 3 | 4 | 23 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | 1 | 2 | — | 3 | 10 | 15 |
| Polypoidal choroidal vasculopathy | D000092342 | — | — | 1 | 1 | — | 7 | 4 | 12 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 4 | 5 | 9 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | — | — | 1 | 2 | 4 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | 1 | 1 | 2 |
| Polyps | D011127 | EFO_0000662 | — | — | — | — | 1 | — | 1 |
| Visual acuity | D014792 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic neovascularization | D009389 | — | — | 1 | 3 | 2 | — | 4 | 8 |
| Myopia | D009216 | EFO_0003927 | H52.1 | 1 | — | 1 | — | 1 | 3 |
| Retinal neovascularization | D015861 | — | H35.05 | — | 1 | 2 | — | — | 2 |
| Degenerative myopia | D047728 | — | H44.2 | 1 | — | 1 | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | 1 | — | — | 2 |
| Basal cell carcinoma | D002280 | — | — | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | — | — | 1 | — | — | 1 |
| Basal cell neoplasms | D018295 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | 1 | — | — | 1 | 2 |
| Histoplasmosis | D006660 | EFO_0007310 | B39 | — | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 2 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
| Vision disorders | D014786 | — | H53.11 | — | 1 | — | — | — | 1 |
| Retinal degeneration | D012162 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | — | — | — | 1 |
| Pleural effusion | D010996 | — | J90 | 1 | — | — | — | — | 1 |
| Malignant pleural effusion | D016066 | — | J91.0 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Choroid diseases | D015862 | — | H31.9 | — | — | — | — | 1 | 1 |
| Dissociative disorders | D004213 | — | F44.1 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Angioid streaks | D000793 | EFO_1000805 | — | — | — | — | — | 1 | 1 |
| White dot syndromes | D000080363 | — | H30.14 | — | — | — | — | 1 | 1 |
| Multifocal choroiditis | D000080364 | — | — | — | — | — | — | 1 | 1 |
| Hereditary eye diseases | D015785 | — | — | — | — | — | — | 1 | 1 |
| Retinoblastoma | D012175 | — | — | — | — | — | — | 1 | 1 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Optical coherence tomography | D041623 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Verteporfin |
| INN | verteporfin |
| Description | (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid is the 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid. It is a beta-substituted porphyrin, a carboxylic acid and a methyl ester. It is functionally related to a (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid. It is an enantiomer of a (2S,2(1)R)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid. |
| Classification | Small molecule |
| Drug class | benzoporphyrin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC |
Identifiers
| PDB | — |
| CAS-ID | 129497-78-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2218885 |
| ChEBI ID | — |
| PubChem CID | 5362420 |
| DrugBank | DB00460 |
| UNII ID | 0X9PA28K43 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,080 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,071 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use